Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell L Shiffman

Showing results (71-80 of 209) with videos related to

Pageof 21
Sort By:
Hepatology (Baltimore, Md.)|March 3, 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinMoises Diago, Mitchell L Shiffman, Jean-Pierre Bronowicki, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 12, 2005
Liver and intestine transplantation: summary analysis, 1994-2003Douglas W Hanto, Thomas M Fishbein, C Wright Pinson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 8, 2004
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African AmericansRichard K Sterling, R Todd Stravitz, Velimir A Luketic, et al.
Hepatology (Baltimore, Md.)|July 9, 2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 resultsYves Benhamou, Nezam H Afdhal, David R Nelson, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
The American Journal of Gastroenterology|September 23, 2003
Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndromeArun J Sanyal, Melissa J Contos, Richard K Sterling, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 2, 2007
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatmentK Rajender Reddy, Mitchell L Shiffman, Timothy R Morgan, et al.
Hepatology (Baltimore, Md.)|June 15, 2007
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alphaMitchell L Shiffman, Jennifer Salvatore, Sarah Hubbard, et al.
The American Journal of Gastroenterology|July 1, 2016
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|March 18, 2009
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT resultsBruce R Bacon, Mitchell L Shiffman, Flavia Mendes, et al.
Pageof 21

Showing results (71-80 of 209) with videos related to

Sort By:
Pageof 21
Hepatology (Baltimore, Md.)|March 3, 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinMoises Diago, Mitchell L Shiffman, Jean-Pierre Bronowicki, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 12, 2005
Liver and intestine transplantation: summary analysis, 1994-2003Douglas W Hanto, Thomas M Fishbein, C Wright Pinson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 8, 2004
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African AmericansRichard K Sterling, R Todd Stravitz, Velimir A Luketic, et al.
Hepatology (Baltimore, Md.)|July 9, 2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 resultsYves Benhamou, Nezam H Afdhal, David R Nelson, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
The American Journal of Gastroenterology|September 23, 2003
Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndromeArun J Sanyal, Melissa J Contos, Richard K Sterling, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 2, 2007
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatmentK Rajender Reddy, Mitchell L Shiffman, Timothy R Morgan, et al.
Hepatology (Baltimore, Md.)|June 15, 2007
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alphaMitchell L Shiffman, Jennifer Salvatore, Sarah Hubbard, et al.
The American Journal of Gastroenterology|July 1, 2016
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|March 18, 2009
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT resultsBruce R Bacon, Mitchell L Shiffman, Flavia Mendes, et al.
Pageof 21